Grifols, S.A. (GIKLY)
GIKLY Stock Price Chart
Explore Grifols, S.A. interactive price chart. Choose custom timeframes to analyze GIKLY price movements and trends.
GIKLY Company Profile
Discover essential business fundamentals and corporate details for Grifols, S.A. (GIKLY) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - General
IPO Date
20 Jan 2010
Employees
23.83K
Website
https://www.grifols.comCEO
Jose Ignacio Abia Buenache
Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
GIKLY Financial Timeline
Browse a chronological timeline of Grifols, S.A. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 24 Feb 2026
Upcoming earnings on 5 Nov 2025
Dividend declared on 30 Jul 2025
A dividend of $0.09 per share was announced, adjusted to $0.09. The dividend was paid on 20 Aug 2025.
Earnings released on 29 Jul 2025
EPS came in at $0.10 falling short of the estimated $0.11 by -11.26%, while revenue for the quarter reached $2.23B , beating expectations by +22.01%.
Earnings released on 12 May 2025
EPS came in at $0.10 surpassing the estimated $0.07 by +29.24%, while revenue for the quarter reached $1.96B , beating expectations by +13.13%.
Earnings released on 26 Feb 2025
EPS came in at $0.05 falling short of the estimated $0.12 by -54.72%, while revenue for the quarter reached $2.05B , beating expectations by +6.49%.
Earnings released on 7 Nov 2024
EPS came in at $0.04 falling short of the estimated $0.11 by -61.44%, while revenue for the quarter reached $1.97B , beating expectations by +2.84%.
Earnings released on 30 Jul 2024
EPS came in at $0.01 falling short of the estimated $0.07 by -83.94%, while revenue for the quarter reached $1.95B , beating expectations by +0.42%.
Earnings released on 14 May 2024
EPS came in at $0.05 falling short of the estimated $0.05 by -14.29%, while revenue for the quarter reached $1.95B , beating expectations by +11.42%.
Earnings released on 31 Mar 2024
EPS came in at $0.02 , while revenue for the quarter reached $1.75B .
Earnings released on 30 Sept 2023
EPS came in at $0.05 falling short of the estimated $0.10 by -54.73%, while revenue for the quarter reached $1.69B , beating expectations by +0.15%.
Earnings released on 30 Jun 2023
EPS came in at $0.05 falling short of the estimated $0.10 by -51.63%, while revenue for the quarter reached $1.81B , missing expectations by -2.17%.
Earnings released on 18 Apr 2023
EPS came in at $0.02 falling short of the estimated $0.08 by -80.02%, while revenue for the quarter reached $1.84B , beating expectations by +9.33%.
Earnings released on 31 Mar 2023
EPS came in at -$0.01 , while revenue for the quarter reached $1.68B .
Earnings released on 30 Sept 2022
EPS came in at $0.03 , while revenue for the quarter reached $1.51B .
Earnings released on 30 Jun 2022
EPS came in at $0.07 falling short of the estimated $0.15 by -53.62%, while revenue for the quarter reached $1.61B , missing expectations by -42.41%.
Earnings released on 29 Apr 2022
EPS came in at -$0.03 , while revenue for the quarter reached $1.36B .
Earnings released on 31 Mar 2022
EPS came in at $0.04 , while revenue for the quarter reached $1.40B .
Earnings released on 30 Sept 2021
EPS came in at -$0.03 , while revenue for the quarter reached $1.39B .
Earnings released on 30 Jun 2021
EPS came in at $0.12 , while revenue for the quarter reached $1.60B , missing expectations by -46.50%.
Dividend declared on 3 Jun 2021
A dividend of $0.22 per share was announced, adjusted to $0.22. The dividend was paid on 14 Jun 2021.
Earnings released on 9 Apr 2021
EPS came in at $0.20 surpassing the estimated $0.11 by +79.41%, while revenue for the quarter reached $1.61B , beating expectations by +10.29%.
Earnings released on 31 Mar 2021
EPS came in at $0.11 , while revenue for the quarter reached $1.39B .
Dividend declared on 30 Oct 2020
A dividend of $0.10 per share was announced, adjusted to $0.10. The dividend was paid on 9 Nov 2020.
Earnings released on 30 Sept 2020
EPS came in at $0.25 surpassing the estimated $0.16 by +58.39%, while revenue for the quarter reached $1.59B , missing expectations by -0.32%.
GIKLY Stock Performance
Access detailed GIKLY performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.